-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis

Benzinga·09/21/2026 06:32:59
Listen to the news
  • Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profile
  • Clinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological difference